---
id: trial_003
type: clinical_trial
topic: Migraine prevention
disease: Chronic migraine
molecule: Atogepant
phase: Phase 3
status: Completed
---

Trial: PROGRESS - Atogepant for Chronic Migraine Prevention

Sponsor: AbbVie
Enrollment: 778 patients
Duration: 12 weeks
Population: Adults with chronic migraine (≥15 headache days/month)

Primary Endpoint: Change in mean monthly migraine days (MMD)

Results:
- Atogepant 60mg BID: -7.5 MMD reduction vs -5.1 placebo (p<0.001)
- ≥50% reduction in MMD: 41% vs 26% placebo
- Improvement in Migraine-Specific Quality of Life questionnaire

Safety:
- Constipation (11% vs 3% placebo)
- Nausea (8% vs 4% placebo)
- Weight decrease reported in 4%
- Hepatic safety: No ALT elevations >3x ULN
- No drug interactions with oral contraceptives

Conclusion: First oral CGRP antagonist approved for chronic migraine prevention. Offers convenience advantage over injectable anti-CGRP antibodies. Approved September 2023.

